Janux Therapeutics surged on promising early data and M&A rumors in 2024, but recent clinical updates led to a sharp stock decline. Click for more on JANX.

Deals: Apollo Global Management is in negotiations to acquire Johnson & Johnson’s DePuy Synthes orthopedics business in a ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports.

GSK (LSE: GSK) has delivered a 58.4% share price return over the past five years, putting real pressure on the question of whether current earnings justify ...

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

Tempus AI (NASDAQ:TEM | TEM Price Prediction) is having a breakout week after Morgan Stanley remarks on September 15 ...

Montgomery County isn’t just home to office parks and quiet neighborhoods. It’s one of the most concentrated pharmaceutical ...

At the close on September 16, 2026, GSK stock finished at 1,759,000.00 KRW on Korea Exchange with a 4.08 percent rise. It ...

GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a ...

ASX healthcare stocks are turning to licensing and partnering deals to fund drug development, with Dimerix and Neuren showing ...

All deal values reflect company disclosures. Where parties have not disclosed terms, they are reported as undisclosed. No ...